--Press
--Contact
Press
If you need any further information about MycoTeQ please contact
Henrik Blou, COO
Mobile: (+45) 28 61 68 45
E-mail: henrik.blou@mycoteq.com
or contact us at
MycoTeQ A/S
Universitetsparken 5
DK-2100 København Ø
Denmark
E-mail: info@mycoteq.com
Recent Entries in The Press
Young Antibiotic Company Looking for Financing Opportunities
The R&D based company MycoTeQ in Copenhagen plans to raise capital to develop its antibiotic lead compounds and take them through preclinical studies. The studies focus on activity against multi-resistant bacteria. The company raised capital from Novo Seeds in the spring this year.
Journalist: Lisa Kirsebom
Rapidus Newsletter (September 8 2008)
Young Biotech Company will Combat Resistant Bacteria
Novo Seeds, DTU Innovation and Symbion have chosen to invest in the young biotech company MycoTeQ that works with discovery and development of novel antibiotics. "MycoTeQ is an interesting company with a good potential to find novel compounds active against resistant bacteria. Also it is a young biotech company which fits very well with the investment strategy of Novo Seeds" says Søren Carlsen, the Managing Partner of Novo Ventures and Novo Seeds.
Journalist: Morten Jasper
Erhvervsbladet (March 17 2008)
Biotech Baby with cold fungi in the pipeline
The biotech industry attracts high risk capital - but it is a big challenge to pick the winners at the early stages. MycoTeQ is a company focusing on discovery and development of new antibiotics and they have a promising approach. CEO Henrik Blou explains that speed is very important: "Every week counts when you are financed by venture capital".
Venture (December 4 2007)
Lion Goes Mushroom Hunting
R&D Executive Vice President and Chairman of the Board for LEO Pharma, Poul Rasmussen, joins the board of the young biotech company MycoTeQ. The company has access to a comprehensive library of microfungi that includes more than 30,000 unique strains. Poul Rasmussen says:"There must be a lot of interesting molecules in that fungal collection."
Journalist: Tom Frovst
Børsen (February 28 2007)
Few New Biotech Start-ups
The lowest number of start-ups in the Danish biotech sector in many years was the reality of 2006. One of the few new companies created was MycoTeQ. They target the very important area of drug discovery which is also of very high importance to the established pharma companies in the region. Søren Carlsen, partner of the venture fund Novo A/S, adds: "It pays off again for private investors to invest in early phase biotech companies."
Journalist: Mette Holt
Ingeniøren (January 19 2007)
Microfungi as Medicine Factories
MycoTeQ delivers services to biotech and pharma companies. The focus is kept on discovery of new biologically active natural products from microfungi. COO Torsten Bak Requeira adds: "We are particularly good at identifying [...], isolating and transferring the genes involved in the biosynthesis to production strains."
Journalist: Peter Hoffmann
DTU Avisen (January 8 2007)
New Biotech Company on the Hunt among Microfungi
The new biotech company will discover and develop new natural compounds from microfungi for the pharmaceutical industry. The company is named MycoTeQ and is a spin-out from the Technical University of Denmark (DTU). The unique microfungal collection at DTU forms the base for the discovery activities.
Journalist: Tom Frovst
Børsen (December 19 2006)
Scanning Electron Microscopy Photo of Aspergillus versicolor in logo banner and photo of Penicillium chrysogenum below the left menu are used with permission from Rob Samson, Centraalbureau voor Schimmelcultures, Royal Netherlands Academy of Arts and Sciences
